Kala Visvanathan, MD, on Clinical Implications of Using Cholesterol-Lowering Drugs to Treat Ovarian Cancer

Posted: Tuesday, August 11, 2020

Kala Visvanathan, MD, of Johns Hopkins Bloomberg School of Public Health, discusses the implications of her study findings, which suggest that atorvastatin and simvastatin, lipophilic statin cholesterol-lowering drugs, reduce ovarian cancer mortality. The next step is to see whether these well-tolerated, accessible, and inexpensive drugs could play an important role in the global burden of ovarian cancer.